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Case Report

Valproate induced myopathy-a different presentation of
an uncommon condition
Saumya H Mittal*, Shivananda Pai, Misri Z K, Rohith Pai
Email: saumyamittal1@gmail.com

Abstract
We report the case of an 11-year-old girl, who presented with weakness of legs for 20 days at presentation. The
symptoms started soon after the initiation of sodium valproate for generalized seizures. The patient was found to
have carnitine deficiency. Majority of the reports suggest that valproate induced myopathy occurs months after
the onset of treatment. We report this case where the myopathy developed within days of onset of treatment
with valproate. This may have been the reason why the patient showed no changes in EMG. The patient also
showed no significant risk factor for the predisposition to the carnitine deficiency secondary to valproic acid
therapy. No other complication of the carnitine deficiency was noted in our patient.
Key words: Carnitine deficiency, valproate induced myopathy, valproate side effects

Introduction
Sodium valproate, a significant antiepileptic drug
is known to cause common side-effects like nausea,
vomiting, weight gain, alopecia etc. This may
include myopathy, which occurs after a few months
of therapy. We present a case developing within
days of initiation of therapy.1
Case report
An 11-year-old girl was presented to the hospital
with complaints of difficulty in walking upstairs,
observed initially while climbing the bus to school,
for past 20 days. The weakness was experienced in
both the legs. Additionally, there was an associated
history of difficulty in getting up from the squatting
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position. There was no history of slippage of slippers
and no symptoms in the upper limbs. Further,
no similar family history was recorded. After an
examination, the patient was found to have normal
reflexes and mild neck flexor weakness was noted.
No sensory symptoms or signs were detected. The
patient’s prior medical history referred to episodes of
generalized seizures for which, she had been initiated
on sodium valproate. The mother insisted that the
symptoms had begun one day after the initiation of
the antiepileptic medicine. The patient was found to
have normal electrolytes, liver function test, renal
function tests and thyroid function tests. The patient
was found to have a normal creatine kinase, nerve
conduction study and electromyography (CPK,
NCS, EMG respectively). Serum carnitine levels
were 16 µmoles/L (normal range 25-54 µmoles/L).
In view of the onset of weakness after the initiation
of sodium valproate, the medicine was changed.
Thereafter, she recovered in 3 to 4 days. Carnitine
supplementation was initiated as well.
Discussion
Interestingly, the cases similar to the aforementioned
case are relatively few. All the cases reported
exhibited mostly lower limb symptoms compared
to upper limb symptoms. All cases had normal
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CPK and NCS reports.1,2 In both the reports, the
presentation of the weakness was comparatively late
and noticeable after months. In the aforementioned
case, the presentation occurred within days. In
contrast with the reports in other cases, our patient
had a normal EMG. This may be attributed to an
early presentation of the weakness as compared to
the other reports. 3
Similar to the other reports, our patient also
showed a low carnitine levels.1,2 Carnitine, a protein
synthesized from lysine and methionine, acts as a
transmembrane carrier in the mitochondria for the
long chain fatty acids. It plays a significant role
in utilizing fats as a source of energy in muscles.2
Carnitine physiology is the basis of metabolic
deficits, predominantly in the type 1 skeletal muscle
fibres. The type 1 fibres are slow twitch oxidative
fibres. Carnitine deficiency results in a lipid storage
myopathy involving the type1 fibres and leads to
hypotonia and weakness. There is also associated
myolysis and atrophy of type 2 fibres.4
Most often, decreased carnitine levels have no
pathological significance. In many instances,
children show no symptomatic manifestations
due to carnitine deficiency.2 A state of carnitine
insufficiency may exist between frank deficiency of
carnitine and normal levels of carnitine. Obesity,
cancer, renal disease (and its treatment-dialysis)
and endocrine conditions (diabetes mellitus and
hypothyroidism) are amongst the conditions that
lead to carnitine insufficiency.4 Our patient showed
none of these conditions.
Valproic acid is a commonly used antiepileptic
drug, useful for a broad range of seizures such
as idiopathic generalized epilepsy, symptomatic
seizures, Lennox Gastaut syndrome, West syndrome,
Landau Kleffner syndrome, etc. It has also been
used in the management of the painful diabetic
neuropathy and peripheral nerve injury. Treatment
of migraine and its prophylaxis also involve the
usage of valproate. Moreover, valproate has found
its use in tardive dyskinesia and chorea. Due to
its effectiveness in anticancer activity, its usage
was permitted in suppression of tumour growth,
metastasis and induction of tumour differentiation
2
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for ovarian carcinoma. It inhibits toxoplasma gondii,
mycobacterium smegmatis and staphylococcus
aureus. Valproic acid has a mood stabilizing effect
as observed in cases of Alzheimer’s disease and in
panic attacks (not responsive to antidepressants).5,6,7
However, it has its share of side effects (Table 1).
Table 1: Side effects of Valproate
1 Gastrointestinal side effectsNausea, vomiting, diarrhoea, abdominal cramps
Hepatotoxicity and pancreatitis especially in children
2 Hematological side effectsNeutropenia, coagulation disorders, pseudolymphoma
syndrome
3 Pediatric populationHepatotoxicity and pancreatitis - therefore, it should be
avoided in children.
Reduced bone mass and growth.
Significant increase in weight and BMI with reduced
height.
Fetal valproate syndrome (developmental delay, typical
facies, and malformations)
4 OncologicalEndometrial adenocarcinoma and breast cancer
5 Obstretics and Gynecological effects
Teratogenic effects- limb defects, neural tube defects
and spina bifida, cardiovascular deformities, craniafacial
defects and skeletal defects- avoid valproate as far as
possible in fertility period.
Menstrual abnormalities, polycystic ovarian syndrome,
increased testosterone levels in women (often without
features of hyperandrogenism).
6 Neurological side effects
Paradoxical aggravation of seizures (in overdoses)
Iatrogenic parkinsonism, dementia and cognitive decline,
metabolic encephalopathy
Pseudoatrophy of the brain.
Reversible neurotoxic symptoms
Acute confusional state, myoclonus and non convulsive
status epilepticus
7 Others
Anticonvulsant hypersensitivity, toxic epidermal
necrolysis, Steven Johnson syndrome.
Onychomadesis, hyperpigmentation, onycholysis.
Subclinical hypothyroidism, increased serum insulin
levels and impaired glucose homeostasis.
Dyslipidemia, metabolic syndrome, and raised LDL.

Valproate and some other drugs e.g. nucleoside
analogues (antiretroviral therapy) and chemotherapy
can lead to reduction of carnitine levels. Valproic
acid can deplete carnitine by several synergistic
mechanisms that include the followinga. Valproic acid is a branched chain fatty
acid. It combines with carnitine to form
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valproylcarnitine. This compound is excreted in
urine. Thereby reducing the levels of carnitine.
b. During an ongoing treatment with valproic
acid, the tubular reabsorption of carnitine and
acyl carnitine is reduced, resulting in further
excretion of carnitine.
c.

Valproic acid inhibits the action of butyrobetaine
hydroxylase, which in turn is significant in the
endogenous production of carnitine.

d. The uptake of carnitine by the cells and
mitochondria is inhibited by both, valproic acid
as well as valproylcarnitine.
e.

Valproic acid combines with mitochondrial
CoA-SH. This inhibits the restoration of
acylcarnitine from the stores of mitochondrial
carnitine. Reduction of CoA-SH levels further
reduces the oxidation of fatty acids and impairs
Adenosine Triphosphate (ATP) production
thereby affecting the action of carnitine
transporter.8

Therefore, valproic acid affects the production,
transport as well as the excretion of carnitine.
Thus so, it reduces the carnitine levels by several
mechanisms. Carnitine deficiency induced by
sodium valproate also causes cardiac problems,
encephalopathy, cerebral edema, hepatotoxicity and
fatigue. Risk factors that predispose to carnitine
deficiency include young age, non-ambulatory
status, underweight children, diet and tube feeding,
neurological disabilities and use of anticonvulsant
drugs etc.2,8
The carnitine deficiency affects the skeletal as
well as cardiac muscles which show a ragged
red appearance on biopsy and increased number
of mitochondria and lipid droplets on electron
microscopy. In relation to this, there is hepatic
steatosis, raised serum glucose and ammonia and
reduced levels of ketones.4 The treatment of
carnitine deficiency is carnitine supplementation,
which results in significant improvement as the
carnitine concentration improves.2

Conclusion
Majority of the reports suggest that valproate
induced myopathy occurs months after the initiation
of treatment. The case discussed so far is significant
precisely because of the fact that myopathy
developed within few days after the initiation of
treatment. This may have been the reason why the
patient exhibited no changes in EMG. Further, the
patient showed no significant risk factor for the
predisposition to the carnitine deficiency secondary
to valproic acid therapy. No other complication of
the carnitine deficiency was noted in our patient.
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